MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why AMRN Stock slipped -0.08% Today — RQD Quant Desk Flash
$12.74 -0.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.71
Amarin Corporation plc (AMRN) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $262.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.71 (-0.20%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMRN)Realized 20D OHLCV Swing Band: ±7.4%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY AMRN SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)
FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (21% of score)
20D Institutional Volume Accumulation (±7.4% realized swing band)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk6/20 pts (-14 pt drag)
Balance-sheet & 10-K footnote risk deducts 14 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$12.03-5.9% Next Q
35
Q2 (-2Q)Grade E$11.32+4.2% Next Q
38
Q3 (-1Q)Grade D$11.79+8.1% Next Q
40
CurrentGrade D-$12.74-6.7% Hist 90D α
43
Trajectory: E (35) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AMRN Turnaround Squeeze
While AMRN currently carries a cautious 43/100 (D-) rating due to SEC 10-K Forensic Risk (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.97) and Max Pain ($13.38) forces dealer call-delta covering toward $18.18.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AMRN Stock slipped -0.08% Today — RQD Quant Desk Flash
Amarin Corporation plc (AMRN) slipped -0.08% to $12.74, trading at 25% of its 52-week range ($11.25 – $17.31). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 25% of its 52-week range ($11.25 – $17.31) with RSI-14 at 46.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.4% around $12.74 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 56.6% gross margin and $6.7M annual free cash flow.
Live AMRN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMRN)
- ✓Walkthrough of AMRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.54%⚡ TESTING RESISTANCE
2026-10-30O $12.71H $12.76L $12.00C $12.74VOL 101.3K
RES: $13.25SUP: $10.87SMA50: $12.97SMA200: $14.31
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AMRN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AMRN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRN)
Health Care Rank #547 of 1016
⚔️ QTTB vs AMRN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AMRN vs. QTTB, ABEO, IMRX, BCYC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Amarin Corporation plc (AMRN) ranks #547 by composite RQD confidence (43/100, grade D-) and #538 by equity capitalization ($262.8M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AMRN at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMRN
ACTIVE
Amarin Corporation plc | D- | 43/100 | — | 56.6% | -12.2% | -0.08% | $262.8M | Benchmark Subject |
| QTTB Q32 Bio Inc. | C- | 61/100 | 8.9x | — | 85.0% | -2.10% | $264.1M | /qttb-vs-amrn → |
| ABEO Abeona Therapeutics Inc. | D- | 39/100 | — | 73.7% | -35.0% | +0.22% | $260.8M | /abeo-vs-amrn → |
| IMRX Immuneering Corporation (Class A) | D | 45/100 | — | — | -35.0% | +0.75% | $260.1M | /imrx-vs-amrn → |
| BCYC Bicycle Therapeutics plc | E | 24/100 | — | — | -35.0% | -1.55% | $267.4M | /bcyc-vs-amrn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000897448In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amarin Corporation plc (AMRN) reported GAAP revenue of $213.6M (-6.5% vs. FY2024 revenue of $228.6M , and -30.4% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of $6.7M, and free cash flow of $6.7M (+121.7% YoY). On the balance sheet, AMRN closed FY2025 with $670.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $213.6M | -$38.8M | $6.7M | $6.7M | $670.8M | — |
| FY2024 (FY) | 2024-12-31 | $228.6M | -$87.0M | -$31.0M | -$31.0M | $685.3M | — |
| FY2023 (FY) | 2023-12-31 | $306.9M | -$55.0M | $6.9M | $6.9M | — | — |
3. AMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Amarin Corporation plc (NASDAQ: AMRN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $12.74 (-0.08% 1D, market cap $262.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, AMRN ranks #547 in composite RQD confidence.
How does AMRN compare to QTTB and ABEO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, QTTB (Q32 Bio Inc.) holds a C- grade (61/100 RQD, P/E 8.9x, ROIC 85.0%, cap $264.1M) and ABEO (Abeona Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AMRN?
Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AMRN trading relative to its 50-day, 200-day, and 52-week technical levels?
AMRN last traded at $12.74 (-0.08% on volume of 40,045 shares), positioning the stock -1.77% below its 50-day simple moving average ($12.97) and -10.97% below its 200-day simple moving average ($14.31). Across its 52-week range of $11.25 to $17.31, AMRN sits at the 24.6% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($11.80 to $13.68).
AMRN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AMRN stock moving today?
Why AMRN Stock slipped -0.08% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.